{"id":"W4229458082","doi":"10.1016/s2352-3026(22)00103-x","title":"Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"ca_institutions":"Dalhousie University; Princess Margaret Cancer Centre; Institute of Cancer Research; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Calgary","funders":"Celgene; European Hematology Association; Bristol-Myers Squibb","keywords":"Lenalidomide; Medicine; Multiple myeloma; Dexamethasone; Internal medicine; Clinical endpoint; Transplantation; Autologous stem-cell transplantation; Oncology; Surgery; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001908108,0.002059309,0.002955512,0.0003928126,0.000433335,0.001640748,0.00140966,0.002193376,0.008278829],"category_scores_gemma":[0.001764831,0.0007138695,0.002865864,0.0003980901,0.001527247,0.001702052,0.000633069,0.004826633,0.001368028],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001349774,"about_ca_system_score_gemma":0.001042291,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001419594,"about_ca_topic_score_gemma":0.003636424,"domain_scores_codex":[0.999302,0.0003524396,0.0000306177,0.000137244,0.00004022897,0.0001373745],"domain_scores_gemma":[0.9990566,0.000349383,0.0001698568,0.0000677768,0.00004134082,0.0003150858],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9791433,0.002794787,0.0004759702,0.0005048738,0.0009518705,0.00003513702,0.00005972728,0.0003746172,0.0009482712,0.0001217618,0.0009256947,0.01366403],"study_design_scores_gemma":[0.9748604,0.02303723,0.0009129437,0.00002795265,0.0002615857,0.00002523039,0.00001942662,0.0001704793,0.0001014012,0.0001307119,0.000440013,0.00001268286],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9810157,0.009366122,0.0006189468,0.001708024,0.001020858,0.001993791,0.001400745,0.0001979115,0.002678089],"genre_scores_gemma":[0.9853209,0.003226048,0.001370216,0.002471498,0.0005184247,0.001613396,0.001537997,0.00003546565,0.003906116],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008278829,"threshold_uncertainty_score":0.02769542,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06225182672412834,"score_gpt":0.3657000429541173,"score_spread":0.303448216229989,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}